8-K: Dentsply Sirona Suspends Byte Aligner Sales Amid Regulatory Review, Announces Preliminary Q3 Results and Significant Goodwill Impairment

Dentsply Sirona has temporarily halted sales of its Byte Aligner System and Impression Kits due to a regulatory review, while also reporting preliminary Q3 2024 results including a substantial goodwill impairment.

Summary

• Dentsply Sirona has suspended the sale and marketing of its Byte Aligner System and Impression Kits as a precautionary measure while reviewing regulatory requirements.
• The company's decision was made in consultation with the U.S. Food and Drug Administration (FDA).
• Preliminary Q3 2024 net sales are expected to be approximately $951 million, with adjusted earnings per share (EPS) between $0.49 and $0.51.
• Essential Dental Solutions saw year-over-year net sales growth, while Orthodontic and Implant Solutions and Connected Technology Solutions segments experienced declines.
• Wellspect Healthcare net sales are expected to be approximately flat.
• A shift in distributor orders for Essential Dental Solutions from Q4 to Q3 positively impacted net sales and adjusted EPS by approximately $20 million.
• The company expects to record non-cash goodwill impairment charges between $450 and $550 million, net of tax, related to Orthodontic Aligner Solutions and Implant & Prosthetic Solutions.
• The impairment is due to adverse regulatory trends, weakened demand, competitive pricing pressures, and global conflicts.
• The suspension of Byte sales is expected to have a material impact on the company's results, as Byte products represent approximately 5% of annual revenue.
• The company will provide further updates on its business and 2024 outlook during its Q3 2024 earnings call on November 7, 2024.

Sentiment

Score: 3

Explanation: The document contains significant negative news including a product suspension, a large goodwill impairment, and declining sales in key segments. While there are some positives, the overall tone is negative from an investment perspective.

Positives

• Essential Dental Solutions experienced year-over-year net sales growth in Q3 2024.
• A shift in distributor orders positively impacted net sales and adjusted EPS by approximately $20 million.
• The company is proactively working with the FDA to address regulatory concerns.
• Dentsply Sirona is assessing resources at Byte to leverage and/or redeploy infrastructure, talent, and capability elsewhere in the business.

Negatives

• The company is suspending sales of its Byte Aligner System and Impression Kits, which will materially impact results.
• Orthodontic and Implant Solutions and Connected Technology Solutions segments experienced net sales declines in Q3 2024.
• The company expects to record a significant non-cash goodwill impairment charge between $450 and $550 million, net of tax.
• The impairment is due to adverse regulatory trends, weakened demand, competitive pricing pressures, and global conflicts.
• The Byte Aligner business has been negatively impacted by state regulatory trends.

Risks

• Failure to promptly resolve regulatory issues could lead to FDA actions such as fines, injunctions, or product recalls.
• The suspension of Byte sales will have a material adverse impact on the company's financial results.
• The company may incur additional impairments and write-offs related to the Byte business.
• The preliminary financial results are subject to change based on the completion of quarter-end closing procedures.
• Ongoing global conflicts and competitive pricing pressures are negatively impacting the Implant & Prosthetic Solutions segment.

Future Outlook

The company will provide an update to its 2024 full year outlook during its third quarter 2024 earnings call on November 7, 2024.

Management Comments

• The company holds itself to the highest standards of quality and compliance with patient safety at the center of everything we do.
• We will continue to work closely with the FDA and other regulatory authorities, while communicating with treating dentists and their patients to support their continued care as appropriate.

Industry Context

The suspension of Byte aligner sales highlights the increasing regulatory scrutiny in the direct-to-consumer orthodontics market, and the challenges of balancing innovation with compliance. This may impact other companies in the space.

Comparison to Industry Standards

• The goodwill impairment of $450-$550 million is significant and suggests a substantial re-evaluation of the value of the Orthodontic and Implant Solutions segment, particularly the Byte business.
• Competitors in the dental aligner market, such as Align Technology (ALGN), have also faced regulatory challenges, but the scale of Dentsply Sirona's impairment suggests a more severe impact.
• The shift in distributor orders impacting revenue by $20 million is a notable event, and it will be important to see if this is a one-off event or a trend.
• The company's overall performance will be compared to other large dental product manufacturers like Straumann and Envista, to assess its relative strength in the market.

Stakeholder Impact

• Shareholders will be negatively impacted by the goodwill impairment and suspension of Byte sales.
• Employees in the Byte division may be affected by the assessment of resources and potential redeployment.
• Customers of Byte aligners may experience disruptions in service and product availability.
• Suppliers to the Byte business may see a reduction in orders.

Next Steps

• The company will evaluate and assess the appropriate next steps for the Byte business.
• The company will provide further updates on the business and its performance during its Q3 2024 earnings call on November 7, 2024.
• The company will continue to work closely with the FDA and other regulatory authorities.

Key Dates

Keywords

Dentsply Sirona, Byte Aligner, FDA, Regulatory Review, Goodwill Impairment, Q3 2024 Results, Dental Solutions, Orthodontics, Implants, Net Sales, EPS